---
title: "Sionna Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286086839.md"
datetime: "2026-05-12T11:10:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286086839.md)
  - [en](https://longbridge.com/en/news/286086839.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286086839.md)
---

# Sionna Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.6, missing the estimate of USD -0.5156.

EBIT: As of FY2026 Q1, the actual value is USD -32.42 M.

#### Financial Results for the Quarter Ended March 31, 2026

-   **Research and Development Expenses**: Sionna Therapeutics, Inc.’s research and development expenses were $19.0 million for the first quarter of 2026, an increase from $13.7 million for the first quarter of 2025, primarily due to development expenses for the clinical pipeline and personnel-related costs .
-   **General and Administrative Expenses**: General and administrative expenses increased to $10.6 million for the first quarter of 2026, compared to $6.0 million for the first quarter of 2025, mainly due to personnel-related costs .
-   **Net Loss**: The company reported a net loss of -$26.8 million for the first quarter of 2026, wider than the net loss of -$16.5 million for the first quarter of 2025 .
-   **Net Loss per Share, Basic and Diluted**: Net loss per share was -$0.60 for the first quarter of 2026, an improvement from -$0.62 for the first quarter of 2025 .
-   **Weighted-Average Common Shares Outstanding, Basic and Diluted**: The weighted-average common shares outstanding were 44,921,984 for the first quarter of 2026, up from 26,596,059 for the first quarter of 2025 .
-   **Interest Income**: Interest income was $2.82 million for the first quarter of 2026, a decrease from $3.0 million for the first quarter of 2025 .
-   **Other Income**: Other income was -$0 thousand for the first quarter of 2026, compared to $177 thousand for the first quarter of 2025 .

#### Selected Consolidated Balance Sheet Data (in thousands)

-   **Cash, Cash Equivalents, and Marketable Securities**: As of March 31, 2026, cash, cash equivalents, and marketable securities totaled $289,931 thousand, a decrease from $310,302 thousand as of December 31, 2025 .
-   **Working Capital**: Working capital was $211,183 thousand as of March 31, 2026, down from $229,707 thousand as of December 31, 2025 .
-   **Total Assets**: Total assets were $305,039 thousand as of March 31, 2026, compared to $325,953 thousand as of December 31, 2025 .
-   **Total Stockholders’ Equity**: Total stockholders’ equity stood at $288,208 thousand as of March 31, 2026, a decrease from $306,833 thousand as of December 31, 2025 .

#### Operational Highlights

-   Enrollment was completed in the PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 .
-   A Phase 1 trial is currently evaluating NBD1 stabilizer SION-451 in proprietary dual combinations with SION-2222 and SION-109 in healthy volunteers .
-   Encore data from the 2025 North American Cystic Fibrosis Conference is scheduled to be presented at the 49th European Cystic Fibrosis Conference in June 2026 .

#### Outlook / Guidance

Sionna Therapeutics, Inc. anticipates releasing topline data for the SION-719 Phase 2a trial and the SION-451 Phase 1 dual combination trial in the summer of 2026 . The company maintains a strong cash position of approximately $289.9 million . This cash position is expected to fund operations into 2028 .

### Related Stocks

- [SION.US](https://longbridge.com/en/quote/SION.US.md)

## Related News & Research

- [LifeSci Capital Reaffirms Their Buy Rating on Sionna Therapeutics, Inc. (SION)](https://longbridge.com/en/news/286649459.md)
- [Sionna Therapeutics Q1 net loss widens, misses estimates](https://longbridge.com/en/news/286086578.md)
- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [Keysight Technologies Reports Second Quarter 2026 Results | KEYS Stock News](https://longbridge.com/en/news/286959830.md)